Pharvaris Highlights Clinical Progress in HAE Treatment
At the recent AAAAI/WAO Joint Congress, Pharvaris presented compelling long-term clinical data supporting the use of deucrictibant, a novel oral treatment for hereditary angioedema (HAE). This data underscores the drug's potential to not only prevent but also effectively address HAE attacks, offering hope to those afflicted by this debilitating condition.
Key Findings from the CHAPTER-1 OLE Study
The CHAPTER-1 Open-Label Extension (OLE) study provides insights into the efficacy of deucrictibant over a significant treatment period. Participants reported a marked reduction in monthly HAE attack rates, which were maintained for at least 1.5 years. Notably, the median proportion of days with symptoms reached an impressive zero, suggesting a high level of symptom control among those treated with deucrictibant.
Insights on Quality of Life Improvements
Quality of life is a critical metric for people living with chronic conditions. In this study, all participants who completed the 62-week follow-up noted improvements in their health-related quality of life. These findings highlight not only the medical efficacy of deucrictibant but also its potential psychological benefits, particularly in areas such as functioning and emotional well-being.
RAPIDe-2 Extension Study: Promising On-Demand Treatment
Pharvaris is also conducting the RAPIDe-2 extension study, which focuses on the on-demand treatment of HAE attacks. Preliminary results from this study indicate that patients experienced prompt symptom relief, averaging 0.9 hours for upper airway attacks, including those affecting the larynx. This rapid response, consistent with the treatment of non-upper airway attacks, supports the drug's viability in critical situations.
Profound Clinical Implications for Deucrictibant
The consistent findings across both studies show that deucrictibant is generally well tolerated, with no significant safety concerns noted. The ongoing commitment to analyzing clinical outcomes and health-related quality of life metrics reinforces Pharvaris’s confidence in this innovative therapeutic approach.
Understanding Deucrictibant's Mechanism
As a bradykinin B2 receptor antagonist, deucrictibant may play a significant role in preventing HAE attacks. By blocking the activity of bradykinin, which is integral to the physiological pathway that leads to swelling and pain, deucrictibant represents a novel therapeutic class aiming to reduce the frequency and severity of attacks in HAE patients.
Pharvaris’s Commitment to HAE Community
Pharvaris is dedicated to meeting the needs of patients living with HAE by providing an oral treatment option that matches the efficacy of injections while ensuring better tolerability. With both a pivotal Phase 3 study for prophylaxis and another for on-demand treatment in progress, the company is well-positioned to add substantial value to HAE management strategies.
Frequently Asked Questions
What is deucrictibant?
Deucrictibant is an oral bradykinin B2 receptor antagonist developed by Pharvaris for the prevention and treatment of hereditary angioedema (HAE) attacks.
How does deucrictibant work?
By inhibiting bradykinin signaling through the bradykinin B2 receptor, deucrictibant aims to prevent the occurrence of HAE attacks and treat their symptoms effectively.
What were the key results from the CHAPTER-1 study?
The study demonstrated a sustained reduction in monthly HAE attacks and a median of zero days with symptoms, reflecting significant therapeutic success.
How quickly does deucrictibant relieve symptoms?
Data from the RAPIDe-2 study indicated that the median onset of symptom relief was approximately 0.9 hours for upper airway attacks.
What are the next steps for Pharvaris?
Pharvaris continues advancing clinical trials for deucrictibant, focusing on confirming its safety and efficacy in Phase 3 studies for both prophylactic and on-demand treatment of HAE.
